YK-11
Status
No approved product. No FDA-approved labeling exists. No human study is listed in this site's sources, and no approval elsewhere is listed in this site's sources.
What it is
A steroidal compound sold as a SARM with almost no human data.
What published research measured
A steroidal compound derived from a dihydrotestosterone backbone, marketed as a myostatin inhibitor. That description rests on a small number of cell-culture papers from a single research group reporting increased follistatin expression in a muscle cell line. There is no animal efficacy work of any consequence and this entry does not cite any human study — no trials, pharmacokinetics or safety data. Its steroidal structure means the hepatotoxicity and axis-suppression concerns that attach to 17-alpha-alkylated androgens are the relevant precedent, and the absence of published toxicology is an absence of reassurance rather than evidence of safety. Prohibited at all times in sport under WADA class S1.2.
Caution
No FDA-approved labeling exists. No human study is listed in this site's sources, and no approval elsewhere is listed in this site's sources.
Source
Kanno et al., follistatin expression in C2C12 cell culture
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.